期刊文献+

马来酸阿塞那平微球的制备及体外释放研究 被引量:1

Preparation and in vitro release of asenapine maleate-loaded microspheres
原文传递
导出
摘要 目的:制备马来酸阿塞那平(asenapine maleate,ASM)缓释微球,并对其进行体外评价。方法:采用O/W乳化-溶剂挥发法制备ASM微球,研究不同聚合物材料对微球的影响。结果:以PLGA 75/25作为载体制备的ASM微球,球形完整,表面光滑,其粒径为83.54μm,包封率为86.39%,载药量为12.19%,可在40 d内均速或接近均速地释放,其零级释放拟合曲线为:Y=0.022 63X+0.111 45,r=0.986 2。结论:通过乳化-溶剂挥发法所制备的ASM微球在体外可在40 d内持续缓慢释药,以达到长期治疗效果且提高药物的生物利用度,减少给药次数,提高患者顺应性。 Objective:To prepare asenapine maleate (ASM)-loaded microspheres, and evaluate their in vitro characteristics. Methods: ASM microspheres were prepared by O/W emulsion-solvent evaporation method. The effects of different polymers on microspheres were investigated. Results: ASM microspheres prepared with PLGA 75/25 were spherical and smooth. The particle size was 83. 54 μm, the encapsulation efficiency was 86.39% , and the drug loading was 12.19%. The release of ASM was corn speed within 40 days, and the zero-order release curve was as follows: Y = Conclusion : release ASM ASM micro in vitro for sph 40 eres prepared by emulsion-solvent evaporation pleted at a consta 0. 022 63X + 0. 1 method PLGA 75 nearly constant 5,r=0.9862. can sustainedly nt or 114 /25 days, which may achieve long-term therapeutic effect and improve the bioavailability
出处 《中国新药杂志》 CAS CSCD 北大核心 2018年第2期220-224,共5页 Chinese Journal of New Drugs
关键词 马来酸阿塞那平 微球 乳化-溶剂法 缓释 asenapine maleate microsphere emulsion-solvent evaporation method sustained release
  • 相关文献

参考文献4

二级参考文献57

  • 1张立勇,陈云芳.抗精神病药对精神分裂症患者认知功能的影响[J].临床精神医学杂志,2005,15(1):21-22. 被引量:22
  • 2汪开达.精神药理学[M].北京:人民卫生出版社,2007.
  • 3Weber J, McCormack PL. Asenapine[J]. CNS Drugs, 2009, 23(9) -781.
  • 4Marston HM, Young JW, Martin FD, et al. Asenapine effects in animal models of psychosis and cognitive function[J]. Psychopharmacology, 2009, 206 (4): 699.
  • 5Alphs L, Panagides J, Lancaster S. Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale[J]. Psychopharmacol Bull, 2007, 40(2):41.
  • 6Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic[J], lnt J Clin Pract, 2009,63 (12) : 1 762.
  • 7Mclntyre RS. Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder[J]. Expert Rev Neurother, 2010, 10 ( 5 ) : 645.
  • 8Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability[J]. Drugs, 2008, 68(16) :2 269.
  • 9Tarazi FI, Moran-Gates T, Wong EH, et al. Asenapine induces differential regional effects on serotonin receptor subtypes[J]. J Psychopharmacol,2010, 24(3) :341.
  • 10Huang M, Li Z, Dai J, et al. Asenapine increases dopamine, norepinephrine, and acetylcholine effiux in the rat medial prefrontal cortex and hippocampus[J]. Neuropsychopharmacology, 2008, 33 ( 12 ) : 2 934.

共引文献236

同被引文献6

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部